Stephanie Dailey, MD
Nephrology · Louisville, KYNPI 1790717767
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,937 of the $2,749 with a category attached, or 70.5%. Baxter Healthcare accounts for 88.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,468 and has fallen 94.9% since, to $125 in 2025.
Across 23 payments — averaging $119.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$2K
- Travere Therapeutics, Inc.$125
- Otsuka America Pharmaceutical, Inc.$48
- Bristol Myers Squibb$45
- Ultragenyx Pharmaceutical Inc.$25
- Scpharmaceuticals Inc.$19
- plus $44 from 3 others
What the payments were for
- Travel & lodging$1,93770%
- Food & beverage$81230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 14 | $2,444 |
| Travere Therapeutics, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Bristol Myers Squibb | 1 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Filspari$125
How this compares
$2,749 in reported general payments places this provider in the 65th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydralazine Hcl | 61 | $1,051 |
| Potassium Chloride | 29 | $903 |
| Amlodipine Besylate | 141 | $669 |
| Bumetanide | 19 | $657 |
| Losartan Potassium | 44 | $585 |
| Spironolactone | 30 | $485 |
| Hydrochlorothiazide | 78 | $455 |
| Furosemide | 71 | $313 |
| Metoprolol Succinate | 19 | $288 |
| Lisinopril | 35 | $261 |
| Allopurinol | 32 | $161 |
| Olmesartan Medoxomil | 13 | $126 |
| Metoprolol Tartrate | 25 | $94 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Louisville
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Nizar AttallahLouisville$113K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
- Jai BhimaniLouisville$10K
- Alexander AfanasyevLouisville$10K
- William DuffLouisville$9K
- Bhagwan BhimaniLouisville$7K
- Aziz ChamiLouisville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.